Eli Lilly will start selling the two highest doses of its popular weight-loss drug Zepbound directly to customers online in ...

At 12 weeks, weight loss ranged from 2.6% to 11.3%, compared to a gain of 0.2% in the placebo group. Guggenheim analysts were ...

Eli Lilly is reducing the price of the highest doses of its popular drug Zepbound for folks who aren't using insurance.

Johnson & Johnson JNJ has one of the most diverse revenue streams in the industry within the pharmaceutical division called ...

Eli Lilly expands Zepbound access with flat-rate pricing and new vial options, supporting wider obesity treatment access ...

We have recently begun acquiring a new position in Novo Nordisk. Click here for our investment thesis on NVO stock.

Eli Lilly already has a couple of top GLP-1 drugs that help patients with diabetes (Mounjaro) and weight loss (Zepbound), but ...

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...

Part of the appeal of amylin analogs is the potential to drive weight loss without causing the same level of tolerability problems as GLP-1 receptor agonists. Lilly reported relatively low rates of ...

Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See ...

Novo Nordisk’s annual report contains an interesting footnote on its key drug, Ozempic, which last year accounted for $19 ...

Health workers have long relied on Body Mass Index to gauge whether people are within a healthy weight range. Now, top researchers have made the case for a new way to understand and diagnose obesity.